BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates

Stock News

Sep 16

BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as "Baiyunshan Pharmaceutical General Factory"), has recently received "Drug Supplementary Application Approval Notifications" issued by the National Medical Products Administration.

According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.

The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106459077"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106459077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106459077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106459077","market":"fut","top_or_hot":-1,"title":"BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates","media":"Stock News","content":"<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.</p>\n<p>The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-16 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.</p>\n<p>The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0097","symbol_name":"医药电商","start_time":0,"source_url":"","article_id":"1106459077","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106459077","pubTimestamp":1758014063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0097":"医药电商","BK0239":"医药制造","BK1197":"保健护理产品经销商","01477":"欧康维视生物-B","BK0096":"民营医院","BK1521":"挪威政府全球养老基金持仓","BK0183":"MSCI概念","00874":"白云山","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","BK1191":"制药","BK0175":"白马股","BK1606":"中医药概念","BK0070":"员工持股","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK0196":"行业龙头"},"translate_title":"白云山PH(00874)子公司获药品补充申请批准证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"00874":1,"01477":1},"content_text":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.\nAccording to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.\nThe company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}